Tìm theo
Quetiapine
Các tên gọi khác (6 ) :
  • 2-[2-(4-Dibenzo[b,F][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol
  • Quetiapina
  • Quetiapine
  • Quetiapine fumarate
  • Quetiapine hemifumarate
  • Quetiapinum
Thuốc chống rối loạn tâm thần
Thuốc Gốc
Small Molecule
CAS: 111974-69-7
ATC: N05AH04
ĐG : Advanced Pharmaceutical Services Inc.
CTHH: C21H25N3O2S
PTK: 383.507
Quetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also has an antagonistic effect on the histamine H1 receptor.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C21H25N3O2S
Phân tử khối
383.507
Monoisotopic mass
383.166747749
InChI
InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2
InChI Key
InChIKey=URKOMYMAXPYINW-UHFFFAOYSA-N
IUPAC Name
2-[2-(4-{2-thia-9-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-10-yl}piperazin-1-yl)ethoxy]ethan-1-ol
Traditional IUPAC Name
quetiapine
SMILES
OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Độ hòa tan
Moderate
logP
2.8
logS
-4
pKa (strongest acidic)
15.12
pKa (Strongest Basic)
7.06
PSA
48.3 Å2
Refractivity
114.09 m3·mol-1
Polarizability
42.78 Å3
Rotatable Bond Count
5
H Bond Acceptor Count
5
H Bond Donor Count
1
Physiological Charge
1
Number of Rings
4
Bioavailability
1
Rule of Five
true
Ghose Filter
true
Dược Lực Học : Quetiapine is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Quetiapine is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), and dopamine type 2 (D2) receptors. Quetiapine is an antagonist at serotonin 5-HT1A and 5HT2, dopamine D1 and D2, histamine H1, and adrenergic alpha 1 and alpha 2 receptors. Quetiapine has no significant affinity for cholinergic muscarinic or benzodiazepine receptors. Drowsiness and orthostatic hypotension associated with use of quetiapine may be explained by its antagonism of histamine H1 and adrenergic alpha 1 receptors, respectively. Quetiapine's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.
Cơ Chế Tác Dụng : Quetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also has an antagonistic effect on the histamine H1 receptor. Quetiapine's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.
Dược Động Học :
▧ Absorption :
Rapidly and well absorbed.
▧ Volume of Distribution :
* 10±4 L/kg
▧ Protein binding :
83%
▧ Metabolism :
Hepatic. The major metabolic pathways are sulfoxidation, mediated by cytochrome P450 3A4 (CYP3A4), and oxidation of the terminal alcohol to a carboxylic acid. The major sulfoxide metabolite of quetiapine is inactive. Quetiapine also undergoes hydroxylation of the dibenzothiazepine ring, O-deakylation, N-dealkylation, and phase II conjugation. The 7-hydroxy and 7-hydroxy- N-delakylated metabolites appear to be active, but are present in very low concentrations.
▧ Route of Elimination :
Elimination of quetiapine is mainly via hepatic metabolism. Following a single oral dose of 14C-quetiapine, less than 1% of the administered dose was excreted as unchanged drug, indicating that quetiapine is highly metabolized. Approximately 73% and 20% of the dose was recovered in the urine and feces, respectively.
▧ Half Life :
6 hours
Độc Tính : Symptoms of overdose include drowsiness and sedation, tachycardia, and hypotension.
Chỉ Định : For the treatment of schizophrenia and related psychotic disorders.
Tương Tác Thuốc :
  • Artemether Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Clarithromycin The macrolide, clarithromycin, may increase the effect and toxicity of quetiapine.
  • Donepezil Possible antagonism of action
  • Erythromycin The macrolide, erythromycin, may increase the effect and toxicity of quetiapine.
  • Ethotoin Phenytoin decreases the effect of quetiapine
  • Etravirine Quetiapine, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase quetiapine dosage if concurrent therapy is required.
  • Fosphenytoin Phenytoin decreases the effect of quetiapine
  • Galantamine Possible antagonism of action
  • Ketoconazole Ketoconazole may increase the therapeutic and adverse effects of quetiapine.
  • Lumefantrine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Mephenytoin Phenytoin decreases the effect of quetiapine
  • Phenytoin Phenytoin decreases the effect of quetiapine
  • Quinupristin This combination presents an increased risk of toxicity
  • Rivastigmine Possible antagonism of action
  • Tacrine The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Quetiapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
  • Tacrolimus Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
  • Telithromycin Telithromycin may reduce clearance of Quetiapine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Quetiapine if Telithromycin is initiated, discontinued or dose changed.
  • Tetrabenazine May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
  • Thiothixene May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
  • Toremifene Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
  • Trimethobenzamide Trimethobenzamide and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
  • Trimipramine Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
  • Triprolidine Triprolidine and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
  • Trospium Trospium and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
  • Voriconazole Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of quetiapine by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of quetiapine if voriconazole is initiated, discontinued or dose changed.
  • Vorinostat Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
  • Ziprasidone Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
  • Zuclopenthixol Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Liều Lượng & Cách Dùng : Tablet, film coated - Oral - 100 mg
Tablet, film coated - Oral - 200 mg
Tablet, film coated - Oral - 25 mg
Tablet, film coated - Oral - 300 mg
Tablet, film coated - Oral - 400 mg
Tablet, film coated - Oral - 50 mg
Tablet, film coated, extended release - Oral - 150 mg
Tablet, film coated, extended release - Oral - 200 mg
Tablet, film coated, extended release - Oral - 300 mg
Tablet, film coated, extended release - Oral - 400 mg
Tablet, film coated, extended release - Oral - 50 mg
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty : AstraZeneca
    Sản phẩm biệt dược : Seroquel
  • Công ty :
    Sản phẩm biệt dược : Seroquel XR
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB01224
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=5002
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46504800
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C07397
ChemSpider
http://www.chemspider.com/Chemical-Structure.4827.html
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0310-0275-10
PharmGKB
http://www.pharmgkb.org/drug/PA451201
Wikipedia
http://en.wikipedia.org/wiki/Quetiapine
RxList
http://www.rxlist.com/cgi/generic2/quetiap.htm
PDRhealth
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ser1402.shtml
Drugs.com
http://www.drugs.com/cdi/quetiapine.html
... loading
... loading